Answers are grounded in this paper and cite their sources.
BACKGROUND: For patients with programmed death-ligand 1 (PD-L1)-high non-small cell lung cancer (NSCLC), both immune checkpoint inhibitor (ICI) monotherapy and ICI plus chemotherapy are first-line options, yet optimal subgroups for each remain undefined. We evaluated Ki-67 expression as a biomarker for treatment stratification. METHODS: We retrospectively analyzed 334 advanced PD-L1-high NSCLC cases (2018-2024). Patients were stratified by Ki-67 expression, and outcomes with ICI monotherapy versus ICI-chemotherapy were compared using propensity score matching and multivariable Cox models. RESULTS: After propensity score matching, in the Ki-67 > 30% cohort (n = 166), ICI-chemotherapy was associated with a higher ORR versus ICI monotherapy (32/83, 38.6% vs. 17/83, 20.5%; P = 0.01) and with longer PFS (9.9 vs. 8.4 months; HR 0.51, 95% CI 0.37-0.72; P < 0.001) and OS (22.1 vs. 16.5 months; HR 0.47, 95% CI 0.32-0.70; P < 0.001). In the Ki-67 ≤ 30% cohort (n = 78), ORR was identical (9/39, 23.1%), and no improvement was observed for PFS (8.3 vs. 9.1 months; HR 1.59, 95% CI 0.98-2.59; P = 0.06) or OS (15.7 vs. 20.3 months; HR 1.47, 95% CI 0.85-2.54; P = 0.16). Patients receiving ICI-chemotherapy had more grade ≥ 3 adverse events (40/157, 25.5% vs. 24/177, 13.6%), predominantly hematologic (30/157, 19.1% vs. 3/177, 1.7%). CONCLUSION: Ki-67 expression may represent a potential predictive biomarker for identifying PD-L1-high NSCLC patients more likely to benefit from chemo-immunotherapy, though its clinical utility requires confirmation in prospective, randomized studies.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: